AR
VRTX icon

Advisory Research’s Vertex Pharmaceuticals VRTX Stock Holding History

Advisory Research’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,092
Closed -$380K – 478
2023
Q3 		$380K Buy
1,092
+8
+0.7% +$2.8K 0.05% 323
2023
Q2 		$381K Buy
+1,084
New +$365K 0.05% 339
2018
Q4 		– Sell
-1,144
Closed -$220K – 401
2018
Q3 		$220K Buy
+1,144
New +$204K ﹤0.01% 352
2018
Q2 		– Sell
-1,500
Closed -$244K – 397
2018
Q1 		$244K Sell
1,500
-435
-22% -$71.1K ﹤0.01% 357
2017
Q4 		$290K Sell
1,935
-319
-14% -$47.2K ﹤0.01% 374
2017
Q3 		$343K Buy
+2,254
New +$339K 0.01% 387
2014
Q2 		– Sell
-863
Closed -$61K – 667
2014
Q1 		$61K Buy
+863
New +$68.3K ﹤0.01% 754

Other funds holding VRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return